Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial

Paul G. Richardson, Pieter Sonneveld, Michael Schuster, David Irwin, Edward Stadtmauer, Thierry Facon, Jean Luc Harousseau, Dina Ben-Yehuda, Sagar Lonial, Hartmut Goldschmidt, Donna Reece, Jesus San Miguel, Joan Bladé, Mario Boccadoro, Jamie Cavenagh, Melissa Alsina, S Vincent Rajkumar, Martha Lacy, Andrzej Jakubowiak, William DaltonAnthony Boral, Dixie Lee Esseltine, David Schenkein, Kenneth C. Anderson

Research output: Contribution to journalArticle

433 Citations (Scopus)

Abstract

Initial analysis of the Assessment of Proteasome Inhibition for Extending Remissions (APEX) trial of relapsed multiple myeloma patients showed significantly longer time to progression, higher response rate, and improved survival with single-agent bortezomib versus high-dose dexamethasone. In this updated analysis (median follow-up: 22 months), survival was assessed in both arms, and efficacy updated for the bortezomib arm. Median survival was 29.8 months for bortezomib versus 23.7 months for dexamethasone, a 6-month benefit, despite substantial crossover from dexamethasone to bortezomib. Overall and complete response rates with bortezomib were 43% and 9%, respectively; among responding patients, 56% improved response with longer therapy beyond initial response, leading to continued improvement in overall quality of response. Higher response quality (100% M-protein reduction) was associated with longer response duration; response duration was not associated with time to response. These data confirm the activity of bortezomib and support extended treatment in relapsed multiple myeloma patients tolerating therapy. This study is registered at http://clinicaltrials.gov (Study ID NCT00048230).

Original languageEnglish (US)
Pages (from-to)3557-3560
Number of pages4
JournalBlood
Volume110
Issue number10
DOIs
StatePublished - Nov 15 2007

Fingerprint

Multiple Myeloma
Dexamethasone
Survival
Proteasome Endopeptidase Complex
Bortezomib
Therapeutics
Survival Rate
Proteins

ASJC Scopus subject areas

  • Hematology

Cite this

Richardson, P. G., Sonneveld, P., Schuster, M., Irwin, D., Stadtmauer, E., Facon, T., ... Anderson, K. C. (2007). Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial. Blood, 110(10), 3557-3560. https://doi.org/10.1182/blood-2006-08-036947

Extended follow-up of a phase 3 trial in relapsed multiple myeloma : Final time-to-event results of the APEX trial. / Richardson, Paul G.; Sonneveld, Pieter; Schuster, Michael; Irwin, David; Stadtmauer, Edward; Facon, Thierry; Harousseau, Jean Luc; Ben-Yehuda, Dina; Lonial, Sagar; Goldschmidt, Hartmut; Reece, Donna; San Miguel, Jesus; Bladé, Joan; Boccadoro, Mario; Cavenagh, Jamie; Alsina, Melissa; Rajkumar, S Vincent; Lacy, Martha; Jakubowiak, Andrzej; Dalton, William; Boral, Anthony; Esseltine, Dixie Lee; Schenkein, David; Anderson, Kenneth C.

In: Blood, Vol. 110, No. 10, 15.11.2007, p. 3557-3560.

Research output: Contribution to journalArticle

Richardson, PG, Sonneveld, P, Schuster, M, Irwin, D, Stadtmauer, E, Facon, T, Harousseau, JL, Ben-Yehuda, D, Lonial, S, Goldschmidt, H, Reece, D, San Miguel, J, Bladé, J, Boccadoro, M, Cavenagh, J, Alsina, M, Rajkumar, SV, Lacy, M, Jakubowiak, A, Dalton, W, Boral, A, Esseltine, DL, Schenkein, D & Anderson, KC 2007, 'Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial', Blood, vol. 110, no. 10, pp. 3557-3560. https://doi.org/10.1182/blood-2006-08-036947
Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial. Blood. 2007 Nov 15;110(10):3557-3560. https://doi.org/10.1182/blood-2006-08-036947
Richardson, Paul G. ; Sonneveld, Pieter ; Schuster, Michael ; Irwin, David ; Stadtmauer, Edward ; Facon, Thierry ; Harousseau, Jean Luc ; Ben-Yehuda, Dina ; Lonial, Sagar ; Goldschmidt, Hartmut ; Reece, Donna ; San Miguel, Jesus ; Bladé, Joan ; Boccadoro, Mario ; Cavenagh, Jamie ; Alsina, Melissa ; Rajkumar, S Vincent ; Lacy, Martha ; Jakubowiak, Andrzej ; Dalton, William ; Boral, Anthony ; Esseltine, Dixie Lee ; Schenkein, David ; Anderson, Kenneth C. / Extended follow-up of a phase 3 trial in relapsed multiple myeloma : Final time-to-event results of the APEX trial. In: Blood. 2007 ; Vol. 110, No. 10. pp. 3557-3560.
@article{73a4381549ec4f8d9e0b144325a5c853,
title = "Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial",
abstract = "Initial analysis of the Assessment of Proteasome Inhibition for Extending Remissions (APEX) trial of relapsed multiple myeloma patients showed significantly longer time to progression, higher response rate, and improved survival with single-agent bortezomib versus high-dose dexamethasone. In this updated analysis (median follow-up: 22 months), survival was assessed in both arms, and efficacy updated for the bortezomib arm. Median survival was 29.8 months for bortezomib versus 23.7 months for dexamethasone, a 6-month benefit, despite substantial crossover from dexamethasone to bortezomib. Overall and complete response rates with bortezomib were 43{\%} and 9{\%}, respectively; among responding patients, 56{\%} improved response with longer therapy beyond initial response, leading to continued improvement in overall quality of response. Higher response quality (100{\%} M-protein reduction) was associated with longer response duration; response duration was not associated with time to response. These data confirm the activity of bortezomib and support extended treatment in relapsed multiple myeloma patients tolerating therapy. This study is registered at http://clinicaltrials.gov (Study ID NCT00048230).",
author = "Richardson, {Paul G.} and Pieter Sonneveld and Michael Schuster and David Irwin and Edward Stadtmauer and Thierry Facon and Harousseau, {Jean Luc} and Dina Ben-Yehuda and Sagar Lonial and Hartmut Goldschmidt and Donna Reece and {San Miguel}, Jesus and Joan Blad{\'e} and Mario Boccadoro and Jamie Cavenagh and Melissa Alsina and Rajkumar, {S Vincent} and Martha Lacy and Andrzej Jakubowiak and William Dalton and Anthony Boral and Esseltine, {Dixie Lee} and David Schenkein and Anderson, {Kenneth C.}",
year = "2007",
month = "11",
day = "15",
doi = "10.1182/blood-2006-08-036947",
language = "English (US)",
volume = "110",
pages = "3557--3560",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Extended follow-up of a phase 3 trial in relapsed multiple myeloma

T2 - Final time-to-event results of the APEX trial

AU - Richardson, Paul G.

AU - Sonneveld, Pieter

AU - Schuster, Michael

AU - Irwin, David

AU - Stadtmauer, Edward

AU - Facon, Thierry

AU - Harousseau, Jean Luc

AU - Ben-Yehuda, Dina

AU - Lonial, Sagar

AU - Goldschmidt, Hartmut

AU - Reece, Donna

AU - San Miguel, Jesus

AU - Bladé, Joan

AU - Boccadoro, Mario

AU - Cavenagh, Jamie

AU - Alsina, Melissa

AU - Rajkumar, S Vincent

AU - Lacy, Martha

AU - Jakubowiak, Andrzej

AU - Dalton, William

AU - Boral, Anthony

AU - Esseltine, Dixie Lee

AU - Schenkein, David

AU - Anderson, Kenneth C.

PY - 2007/11/15

Y1 - 2007/11/15

N2 - Initial analysis of the Assessment of Proteasome Inhibition for Extending Remissions (APEX) trial of relapsed multiple myeloma patients showed significantly longer time to progression, higher response rate, and improved survival with single-agent bortezomib versus high-dose dexamethasone. In this updated analysis (median follow-up: 22 months), survival was assessed in both arms, and efficacy updated for the bortezomib arm. Median survival was 29.8 months for bortezomib versus 23.7 months for dexamethasone, a 6-month benefit, despite substantial crossover from dexamethasone to bortezomib. Overall and complete response rates with bortezomib were 43% and 9%, respectively; among responding patients, 56% improved response with longer therapy beyond initial response, leading to continued improvement in overall quality of response. Higher response quality (100% M-protein reduction) was associated with longer response duration; response duration was not associated with time to response. These data confirm the activity of bortezomib and support extended treatment in relapsed multiple myeloma patients tolerating therapy. This study is registered at http://clinicaltrials.gov (Study ID NCT00048230).

AB - Initial analysis of the Assessment of Proteasome Inhibition for Extending Remissions (APEX) trial of relapsed multiple myeloma patients showed significantly longer time to progression, higher response rate, and improved survival with single-agent bortezomib versus high-dose dexamethasone. In this updated analysis (median follow-up: 22 months), survival was assessed in both arms, and efficacy updated for the bortezomib arm. Median survival was 29.8 months for bortezomib versus 23.7 months for dexamethasone, a 6-month benefit, despite substantial crossover from dexamethasone to bortezomib. Overall and complete response rates with bortezomib were 43% and 9%, respectively; among responding patients, 56% improved response with longer therapy beyond initial response, leading to continued improvement in overall quality of response. Higher response quality (100% M-protein reduction) was associated with longer response duration; response duration was not associated with time to response. These data confirm the activity of bortezomib and support extended treatment in relapsed multiple myeloma patients tolerating therapy. This study is registered at http://clinicaltrials.gov (Study ID NCT00048230).

UR - http://www.scopus.com/inward/record.url?scp=35148825003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35148825003&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-08-036947

DO - 10.1182/blood-2006-08-036947

M3 - Article

C2 - 17690257

AN - SCOPUS:35148825003

VL - 110

SP - 3557

EP - 3560

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -